Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Cash (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Change in Cash for 7 consecutive years, with -$73.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 126.49% to -$73.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$111.1 million through Dec 2025, down 138.51% year-over-year, with the annual reading at -$111.1 million for FY2025, 138.51% down from the prior year.
  • Change in Cash hit -$73.0 million in Q4 2025 for BridgeBio Pharma, up from -$106.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $275.4 million in Q4 2024 to a low of -$198.0 million in Q3 2021.
  • Historically, Change in Cash has averaged $10.7 million across 5 years, with a median of -$4.5 million in 2022.
  • Biggest five-year swings in Change in Cash: soared 2548.19% in 2021 and later tumbled 269.76% in 2025.
  • Year by year, Change in Cash stood at $213.3 million in 2021, then tumbled by 132.3% to -$68.9 million in 2022, then tumbled by 87.82% to -$129.4 million in 2023, then soared by 312.79% to $275.4 million in 2024, then crashed by 126.49% to -$73.0 million in 2025.
  • Business Quant data shows Change in Cash for BBIO at -$73.0 million in Q4 2025, -$106.0 million in Q3 2025, and $208.4 million in Q2 2025.